Abstract
The role of nitric oxide (NO•) as a mediator of cancer phenotype has led researchers to investigate strategies for manipulating in vivo production and exogenous delivery of this molecule for therapeutic gain. Unfortunately, NO• serves multiple functions in cancer physiology. In some instances, NO• or nitric oxide synthase (NOS) levels correlate with tumor suppression and in other cases they are related to tumor progression and metastasis. Understanding this dichotomy has been a great challenge for researchers working in the field of NO• and cancer therapy. Due to the unique chemical and biochemical properties of NO•, its interactions with cellular targets and the subsequent downstream signaling events can be vastly different based upon tumor heterogeneity and microenvironment. Simple explanations for the vast range of NO-correlated behaviors will continue to produce conflicting information about the relevance of NO• and cancer. Paying considerable attention to the chemical properties of NO• and the methodologies being used will remove many of the discrepancies in the field and allow for in depth understanding of when NO-based chemotherapeutics will have beneficial outcomes.
Keywords: Nitric oxide, cancer, metastasis, nitric oxide synthase, chemotherapy
Current Pharmaceutical Design
Title: Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes
Volume: 16 Issue: 4
Author(s): Jason R. Hickok and Douglas D. Thomas
Affiliation:
Keywords: Nitric oxide, cancer, metastasis, nitric oxide synthase, chemotherapy
Abstract: The role of nitric oxide (NO•) as a mediator of cancer phenotype has led researchers to investigate strategies for manipulating in vivo production and exogenous delivery of this molecule for therapeutic gain. Unfortunately, NO• serves multiple functions in cancer physiology. In some instances, NO• or nitric oxide synthase (NOS) levels correlate with tumor suppression and in other cases they are related to tumor progression and metastasis. Understanding this dichotomy has been a great challenge for researchers working in the field of NO• and cancer therapy. Due to the unique chemical and biochemical properties of NO•, its interactions with cellular targets and the subsequent downstream signaling events can be vastly different based upon tumor heterogeneity and microenvironment. Simple explanations for the vast range of NO-correlated behaviors will continue to produce conflicting information about the relevance of NO• and cancer. Paying considerable attention to the chemical properties of NO• and the methodologies being used will remove many of the discrepancies in the field and allow for in depth understanding of when NO-based chemotherapeutics will have beneficial outcomes.
Export Options
About this article
Cite this article as:
Hickok R. Jason and Thomas D. Douglas, Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes, Current Pharmaceutical Design 2010; 16 (4) . https://dx.doi.org/10.2174/138161210790232149
DOI https://dx.doi.org/10.2174/138161210790232149 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways
Current Cancer Drug Targets A Review of Select Recent Patents on Novel Nanocarriers
Recent Patents on Drug Delivery & Formulation Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets Editorial (Hot Topic: Therapeutic Potential of Fetal Mesenchymal Stem Cells)
Current Stem Cell Research & Therapy MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Immunologic Diseases and Brain Tumors
Inflammation & Allergy - Drug Targets (Discontinued) Intractable Cancers: The Many Faces of Multidrug Resistance and the Many Targets it Presents for Therapeutic Attack
Current Drug Targets Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Chlorella vulgaris Induces Apoptosis of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells
Medicinal Chemistry Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry Prediction of the Ebola Virus Infection Related Human Genes Using Protein-Protein Interaction Network
Combinatorial Chemistry & High Throughput Screening MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry